Ser81 Survivin Induced Protein Kinase A (PKA)-dependent Phosphatidylinositol 3-kinase (PI3K) Activity

Ferry Sandra, Roya Khosravi-Far

Abstract


BACKGROUND: Our previous report showed that phosphorylated-survivin at Ser81 induces survivin back loop to activate protein kinase A (PKA) in the cytoprotection mechanism. Activated PKA could possibly induce the cytoprotection via Phosphatydilinositol 3-kinase (PI3K). Therefore our current study was conducted to investigate the possibility of survivin-PKA-PI3K signaling pathway.

METHODS: Viral productions by BOSC23 cells of Survivin, Antisense Survivin (Survivin-AS) and Ser81Ala mutant (Survivin-S81A) in pMSCV-IRES-GFP vector with cytomegalovirus (CMV) promoter were conducted. L929 cells were pretreated with/without PKI 6-22 amide and infected with viral particle of Survivin, Survivin-AS, Survivin-S81A or vector only. Cells were harvested, lysed and immunoprecipitated with anti-PI3K (p85) antibody and immunoblotted to detect PI3K (p85) and phospho-(Tyr) p85 PI3K. To confirm PI3K activation, PI3K Activity Assay was conducted by using phosphoinositide fraction containing PtdIns(4,5)P2 and [32P]ATP.

RESULTS: Immunoblot and PI3K activity results showed similar results. Upon infection of virus with survivin, a markedly increased level of tyrosine phosphorylation of p85 PI3K or PI3K activity in L929 cells was seen. Low levels of tyrosine phosphorylation of p85 PI3K or PI3K activity were observed for Survivin-AS and Survivin-S81A-viral-infected L929 cells. With higher concentrations of Survivin-viral-infection, levels of tyrosine phosphorylation of p85 PI3K or PI3K activity in L929 cells were gradually increased. However, when L929 cells were pretreated with PKI 6-22 amide, prior to Survivin-viral-infection, level of tyrosine phosphorylation level of p85 PI3K or PI3K activity was detected much lower.

CONCLUSION: Our result suggest that Ser81 Survivin play role in inducing PI3K activation and the Survivin-PI3K signaling pathway was PKA-dependent.

KEYWORDS: Ser81, Survivin, PKA, PI3K, L929


Full Text:

PDF

References


Altieri DC. Targeting survivin in cancer. Cancer Lett. 2013; 332: 225-8, CrossRef.

Srinivasula SM, Ashwell JD. IAPs: what's in a name? Mol Cell. 2008; 30: 123-35, CrossRef.

Lens SM, Vader G, Medema RH. The case for Survivin as mitotic regulator. Curr Opin Cell Biol. 2006; 18: 616-22, CrossRef.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351: 2817-26, CrossRef.

Cheung CH, Huang CC, Tsai FY, Lee JY, Cheng SM, Chang YC, et al. Survivin - Biology and potential as a therapeutic target in oncology. Onco Targets Ther. 2013; 6: 1453-62, CrossRef.

Fernández JG, Rodríguez DA, Valenzuela M, Calderon C, Urzúa U, Munroe D, et al. Survivin expression promotes VEGFinduced tumor angiogenesis via PI3K/Akt enhanced β-catenin/ Tcf-Lef dependent transcription. Mol Cancer. 2014; 13: 209, CrossRef.

Sandra F, Khosravi-Far R. Survivin S81A enhanced TRAIL’s activity in inducing apoptosis. Indones Biomed J. 2010; 2: 113-7, CrossRef.

Kawamura K, Fukuda J, Shimizu Y, Kodama H, Tanaka T. Survivin contributes to the anti-apoptotic activities of transforming growth factor alpha in mouse blastocysts through phosphatidylinositol 3'-kinase pathway. Biol Reprod. 2005; 73: 1094-101, CrossRef.

O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA. 2000; 97: 13103-7, CrossRef.

Sandra F, Khosravi-Far R. Phosphorylated-Survivin at Ser81 induced protein linase A (PKA): A back loop. Indones Biomed J. 2011; 3: 138-42, CrossRef.

Sousa LP, Lopes F, Silva DM, Tavares LP, Vieira AT, Rezende BM, et al. PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NFkappaB-independent manner. J Leukoc Biol. 2010; 87: 895-904, CrossRef.

Chen N, Ma WY, Dong Z. Inositol hexaphosphate inhibits ultraviolet B-induced signal transduction. Mol Carcinog. 2001; 31: 139-44, CrossRef.

Hunzicker-Dunn ME, Lopez-Biladeau B, Law NC, Fiedler SE, Carr DW, Maizels ET. PKA and GAB2 play central roles in the FSH signaling pathway to PI3K and AKT in ovarian granulosa cells. Proc Natl Acad Sci USA. 2012; 109: E2979-88, CrossRef.

Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis. 2007; 28: 1379-86, CrossRef.

Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res. 2010; 16: 4325-30, CrossRef.

Newton AC, Trotman LC. Turning off AKT: PHLPP as a drug target. Annu Rev Pharmacol Toxicol. 2014; 54: 537-58, CrossRef.

Lunardi A, Webster KA, Papa A, Padmani B, Clohessy JG, Bronson RT, et al. Role of aberrant PI3K pathway activation in gallbladder tumorigenesis. Oncotarget. 2014; 5: 894-900, CrossRef.

Carnero A, Paramio JM. The PTEN/PI3K/AKT pathway in vivo, cancer mouse models. Front Oncol. 2014; 4: 252, CrossRef.

Hawkins PT, Stephens LR. PI3K signalling in inlammation. Biochim Biophys Acta. 2015; 1851: 882-97, CrossRef.

Qiao M, Sheng S, Pardee AB. Metastasis and AKT activation. Cell Cycle. 2008; 7: 2991-6, CrossRef.




DOI: https://doi.org/10.18585/inabj.v6i3.28

Copyright (c) 2014 The Prodia Education and Research Institute

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

Indexed by:

                  

               

                

 

 

The Prodia Education and Research Institute